logo
logo
CLPT stock ticker logo

ClearPoint Neuro, Inc.

NASDAQ•CLPT
CEO: Mr. Joseph Michael Burnett
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2012-05-22
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Contact Information
120 S. Sierra Avenue, Suite 100, Solana Beach, CA, 92075, United States
888-287-9109
www.clearpointneuro.com
Market Cap
$350.73M
P/E (TTM)
-13.1
23.8
Dividend Yield
--
52W High
$30.10
52W Low
$8.27
52W Range
16%
Rank55Top 80.0%
2.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$10.41M+0.00%
4-Quarter Trend

EPS

-$0.27+0.00%
4-Quarter Trend

FCF

-$12.13M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Revenue Rises 18% Total revenue reached $37.0M USD, marking an 18% increase driven by product sales growth across segments.
Product Sales Surge 28% Product revenue grew 28% to $23.9M USD; neurosurgery disposable sales increased 44% year-over-year.
IRRAS Acquisition Closed Completed IRRAS acquisition in Q4 2025, expanding portfolio into neurocritical care with IRRAflow system integration.
Gross Margin Remains Stable Gross profit reached $22.7M USD; gross margin held steady at 61% despite increased operating costs.

Risk Factors

Net Loss Widens Significantly Net loss increased 35% to $(25.5M) USD in 2025; sustained profitability remains uncertain given ongoing investments.
High Customer Revenue Concentration Significant customer concentration risk exists; top five hospital customers accounted for 21% of 2025 disposable revenues.
Operating Expenses Increase General and administrative expenses rose 38% to $16.5M USD, driven by IRRAS acquisition integration costs.
Market Adoption Uncertainty Future growth hinges on achieving broad market adoption for ClearPoint and IRRAflow systems against established competitors.

Outlook

Anticipated Future Funding Needs Expect need for additional capital following IRRAS acquisition to fund commercialization and integration efforts through 2026.
Expand Installed Base Future objectives depend on expanding installed base and procedure volumes for both ClearPoint and IRRAflow platforms.
Biologics Partner Pipeline Over 60 partners evaluate products for gene/cell therapy delivery; success depends on partner clinical trial outcomes.
Cybersecurity Integration Planned Expect to fully integrate IRRAS cybersecurity governance structure and risk management framework throughout 2026.

Peer Comparison

Revenue (TTM)

INNV stock ticker logoINNV
$912.10M
+13.1%
VREX stock ticker logoVREX
$854.40M
+4.1%
MYGN stock ticker logoMYGN
$824.50M
-1.6%

Gross Margin (Latest Quarter)

LAB stock ticker logoLAB
83.5%
-3.2pp
SIBN stock ticker logoSIBN
79.0%
+0.8pp
AKBA stock ticker logoAKBA
78.8%
+21.3pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
AXGN$2.00B-115.1-13.4%8.7%
TYRA$1.91B-17.7-41.2%2.1%
OLMA$1.47B-9.5-42.9%0.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
7.1%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Deep Research

Next earnings:May 11, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data